Our Systematic Portfolio picked up $XLV on Monday in a decent amount.
I'm not an anti-cancer vaccine expert, nor do I invest in single-name Biotech stocks. I know nothing about the sector.
But this is the benefit of having a systematic approach.
(and yes, it's outperforming
